CCR2: C-C chemokine receptor type 2
Key functional receptor for CCL2 but can also bind CCL7, and CCL12.
- Drugs that act on it: 10
- Approved: 0
- In phases 1 to 3: 10
- Sponsors: 8
Who is on it, and how far along
Every drug ChEMBL records acting on CCR2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 8
- Antibody 1
- Other 1
Approved0
Phase 31
Phase 29
Phase 10
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
| Cenicriviroc | Phase 3 | Tobira Therapeutics | Small molecule | Antagonist | 1 |
| BMS-813160 | Phase 2 | Bristol-Myers Squibb | Small molecule | Antagonist | 1 |
| AZD2423 | Phase 2 | AstraZeneca Pharmaceuticals | Other | Antagonist | 0 |
| BMS-741672 | Phase 2 | Bristol-Myers Squibb | Small molecule | Antagonist | 0 |
| Ilacirnon | Phase 2 | Amgen | Small molecule | Antagonist | 0 |
| JNJ-41443532 | Phase 2 | Johnson & Johnson | Small molecule | Antagonist | 0 |
| MK-0812 | Phase 2 | Merck & Co. (MSD) | Small molecule | Antagonist | 0 |
| PF-04634817 | Phase 2 | Pfizer | Small molecule | Antagonist | 0 |
| PF-4136309 | Phase 2 | Pfizer | Small molecule | Antagonist | 0 |
| Plozalizumab | Phase 2 | Takeda Pharmaceuticals USA | Antibody | InhibitorC-C chemokine receptor type 2 inhibitor | 0 |
| I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients | Cenicriviroc | Phase 2 | Active, not recruiting | QuantumLeap Healthcare Collaborative | Jul 27, 2020 |
| Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | BMS-813160 | Phase 2 | Active, not recruiting | Icahn School of Medicine at Mount Sinai | Oct 10, 2019 |
- Cystic disease of lung0.63
- HIV-1 infection0.38
- Celiac disease0.36
- Rheumatoid arthritis0.36
- COVID-190.35
- Systemic lupus erythematosus0.22
- Hepatic fibrosis0.18
- Metabolic dysfunction-associated steatohepatitis0.17
- Oral ulcer0.16
- Cirrhosis of liver0.16
- Alcohol drinking0.16
- Malabsorption0.15
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4015, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P41597, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets